Literature DB >> 12720532

Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.

Efisio Puxeddu1, Sonia Moretti, Angela Giannico, Marco Martinelli, Cecilia Marino, Nicola Avenia, Roberto Cristofani, Raffaele Farabi, Gianpaolo Reboldi, Rodolfo Ribacchi, Alfredo Pontecorvi, Fausto Santeusanio.   

Abstract

OBJECTIVE: RET proto-oncogene rearrangements (ret/PTCs) represent the most common genetic alterations found in papillary thyroid carcinomas (PTCs). Correlation of ret/PTC expression with clinical outcome is controversial. The aim of the present study was to analyze the frequency of RET rearrangements in adult PTCs, and to investigate if ret/PTCs influence biological behavior and clinical features of the cancers.
DESIGN: Ret/PTC rearrangements were looked for in tIssue samples of 48 PTCs collected at our institution. Data about clinical and pathological features of the tumors were also reviewed. Three separate association analyses were carried out on the cohort evaluating the effects of, respectively, ret/PTC positivity, preferential RET tyrosine kinase domain (RET-TK) expression, and ret/PTC plus RET-TK positivity, on age, sex, tumor size, staging, number of neoplastic foci, and histological subtype.
METHODS: The genetic study was conducted with the RT-PCR-Southern blot technique. Standard Student's t-test and Fisher exact test were applied for the association analyses.
RESULTS: The molecular genetic study demonstrated the positivity of ret/PTC1 and ret/PTC3 in 13 of 48 tumors (27.1%), and an exclusive or preferential RET-TK expression in 17 cases (35.4%). None of the three genetico-clinical analyses showed any significant association between ret/PTC expression and the clinical and pathological features of the cancers.
CONCLUSIONS: These data indicate that RET rearrangements may not play any distinctive role in driving histotype development and cancer progression in these neoplasms. Moreover, they weaken the possibility of using ret/PTC as a prognostic marker for papillary thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720532     DOI: 10.1530/eje.0.1480505

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  13 in total

1.  Differentiated thyroid tumors: surgical indications.

Authors:  R Lucchini; M Monacelli; S Santoprete; R Triola; C Conti; R Pecoriello; P Favoriti; M S Di Patrizi; I Barillaro; A Boccolini; S Avenia; M D'Ajello; A Sanguinetti; N Avenia
Journal:  G Chir       Date:  2013 May-Jun

2.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

3.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

Review 4.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 5.  Thyroid cancer gender disparity.

Authors:  Reza Rahbari; Lisa Zhang; Electron Kebebew
Journal:  Future Oncol       Date:  2010-11       Impact factor: 3.404

6.  Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.

Authors:  Cléber P Camacho; Flavia R M Latini; Gisele Oler; Flavio C Hojaij; Rui M B Maciel; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-22       Impact factor: 3.478

7.  Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Authors:  Carmelo Nucera; Matthew A Nehs; Sushruta S Nagarkatti; Peter M Sadow; Michal Mekel; Andrew H Fischer; Paul S Lin; Gideon E Bollag; Jack Lawler; Richard A Hodin; Sareh Parangi
Journal:  Oncologist       Date:  2011-02-25

8.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

9.  RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma.

Authors:  Cristina Romei; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2012-04-11       Impact factor: 5.555

Review 10.  Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.

Authors:  Young Shin Song; Jung Ah Lim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.